Loading news...
NEW YORK, March 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nutex Health, Inc. ("Nutex" or the "Company") (NASDAQ: NUTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nutex Health, Inc. (“Nutex” or the “Company”) (NASDAQ: NUTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nutex Health, Inc. (NASDAQ: NUTX) breached their fiduciary duties to shareholders.
NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Nutex Health, Inc. (“Nutex” or the “Company”) (Nasdaq: NUTX) for potential violations of the federal securities laws.
NEW YORK, March 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nutex Health, Inc. ("Nutex" or the "Company") (NASDAQ: NUTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Nutex Health (NASDAQ: NUTX - Get Free Report) and Omada Health (NASDAQ: OMDA - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends. Institutional and Insider Ownership 5.3% of Nutex
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Nutex Health, Inc. (“Nutex” or the “Company”) (Nasdaq: NUTX) for potential violations of the federal securities laws.
Nutex Health Inc. (NUTX) Q4 2025 Earnings Call Transcript
ATLANTA, March 06, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Nutex Health, Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX) complied with federal securities laws. On March 5, 2026, Nutex Health announced its financial and operating results for the fourth quarter and fiscal year 2025, revealing a revenue decrease of $105.9 to $151.7 million for the three months ended December 31, 2025 due in part to a “one-time $55.0 million cumulative true-up of 18,950 arbitration claims that arbitrators determined were ineligible under the IDR process. ” The price of the Company's stock dropped following this news.
Block & Leviton is investigating Nutex Health, Inc. (Nasdaq: NUTX) for potential securities fraud. Investors should contact the firm to recover losses.
FULL YEAR 2025 HIGHLIGHTS: Total revenue of $875.3 million for the year 2025 versus $479.9 million for the year 2024, an increase of 82.4% Net income attributable to Nutex Health of $70.8 million for 2025 versus net income of $52.1 million for 2024, an increase of $18.7 million Diluted EPS of $10.48 for 2025 versus diluted EPS of $9.69 for 2024 EBITDA of $168.6 million for 2025 versus $98.8 million for 2024, an increase of 70.6% Adjusted EBITDA of $259.6 million for 2025 versus $102.8 million for 2024, an increase of 152.6% Net cash from operating activities of $248.1 million for 2025 HOUSTON, March 5, 2026 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), today announced fourth quarter and fiscal year 2025 financial results for the twelve months ended December 31, 2025. Nutex Health is a physician-led, healthcare services and operations company with 27 hospital facilities in 12 states (hospital division), and a primary care-centric, risk-bearing physician network.
New York, New York--(Newsfile Corp. - March 5, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nutex Health, Inc. (NASDAQ: NUTX) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Nutex Health caused the company to misrepresent or fail to disclose that: (i) HaloMD was achieving lucrative arbitration results for Nutex by engaging in a coordinated scheme to defraud insurance companies; (ii) as a result, to the extent that they were the product of fraudulent conduct, revenues attributable to the Company's engagement with HaloMD in the IDR process were unsustainable; (iii) in addition, the Company overstated the extent to which it had remediated, and/or its ability to remediate, the material weaknesses in its internal controls over financial reporting; (iv) as a result, the Company was unable to effectively account for the treatment of certain of its stock based compensation obligations; (v) as a result, Nutex improperly calculated these stock based compensation obligations as equity rather than liabilities; (vi) the foregoing increased the risk that the Company would be unable to timely file certain financial reports with the SEC; (vii) accordingly, Nutex's business and/or financial prospects were overstated; and (viii) as a result, public statements were materially false and misleading at all relevant times.
Nutex Health is rated a buy, driven by the potential passage of the No Surprises Enforcement Act. NUTX's $387 million in receivables could rapidly convert to cash if the bill passes, eliminating a key valuation overhang. The company trades at 5.2x P/E despite 49% projected 2026 revenue growth and a 27% TTM operating margin, reflecting market skepticism over payment collections.
HOUSTON, Feb. 25, 2026 /PRNewswire/ -- Nutex Health, Inc. (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 27 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced that it plans to file its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025, on Thursday, March 5, 2026, after the market close. The Company will also issue a corresponding press release summarizing financial results on the same day.
Principal Financial Group Inc. purchased a new stake in Nutex Health Inc. (NASDAQ: NUTX) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 9,314 shares of the company's stock, valued at approximately $962,000. Principal Financial Group Inc. owned
Medpace (NASDAQ: MEDP - Get Free Report) and Nutex Health (NASDAQ: NUTX - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, analyst recommendations and risk. Profitability This table compares Medpace and Nutex Health's net
Exploring the Investment Strategies of John Hussman (Trades, Portfolio) in Q4 2025 John Hussman (Trades, Portfolio) recently submitted the 13F filing for the f
HOUSTON, Jan. 12, 2026 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 27 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced the reopening of Bayou City ER & Hospital, located northeast of Houston at 19211 McKay Dr., Humble, Texas. The staff of medical experts at Bayou City ER & Hospital are bringing the community 24/7/365 days of concierge-level care.
HOUSTON, Jan. 5, 2026 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 26 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced that the Company's CEO, Dr. Tom Vo, CFO, Mr. Jon Bates, and President, Dr. Warren Hosseinion will attend and present at the 2026 J.P.
Embecta (NASDAQ: EMBC - Get Free Report) and Nutex Health (NASDAQ: NUTX - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings. Analyst Recommendations This is a summary of current